Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab Autoinjector vs Prefilled Syringe in Postmenopausal Osteoporosis
NCT03432533Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started Feb 2018; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT03432533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432533.